search
Back to results

Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity (STEP 7)

Primary Purpose

Overweight, Obesity, Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Semaglutide
Placebo (semaglutide)
Sponsored by
Novo Nordisk A/S
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Overweight

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female, age 18 years or older at the time of signing informed consent
  • History of at least one self-reported unsuccessful dietary effort to lose body weight

For subjects without T2D at screening:

  • Body mass index (BMI) of :
  • greater than or equal to 30 kg/m^2
  • greater than or equal to 27 kg/m^2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease

For subjects with T2D at screening:

  • Diagnosed with T2D above or equal to 180 days prior to the day of screening
  • Treated with either:
  • diet and exercise alone or
  • stable treatment (same drug(s), dose and dosing frequency) for at least 60 days prior to the day of screening with up to 3 oral antidiabetic medications alone or in any combination (metformin, α-glucosidase inhibitor (AGI), SU, glinides, SGLT2i or glitazone) according to local label
  • HbA1c 7.0-10.0% (53-86 mmol/mol) (both inclusive)
  • BMI greater than or equal to 27 kg/m^2

Exclusion Criteria:

  • A self-reported change in body weight above 5 kg (11 lbs) within 90 days before screening irrespective of medical records

For subjects without T2D at screening:

- HbA1c equal to or above 6.5% (48 mmol/mol) as measured by the central laboratory at screening

For subjects with T2D at screening:

  • Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of below 30 mL/min/1.73 m^2 (below 60 mL/min/1.73 m^2 in subjects treated with SGLT2i) according to CKDEPI creatinine equation as defined by KDIGO 2012 by the central laboratory at screening
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.

Sites / Locations

  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Semaglutide

Placebo (semaglutide)

Arm Description

Once-weekly injections of gradually increased doses of semaglutide

Once-weekly injections of gradually increased doses of semaglutide placebo

Outcomes

Primary Outcome Measures

Change in body weight
Percent
Subjects who achieve body weight reduction equal to or above 5% (yes/no)
Number of subjects

Secondary Outcome Measures

Subjects who achieve body weight reduction equal to or above 10% (yes/no)
Number of subjects
Subjects who achieve body weight reduction equal to or above 15% (yes/no)
Number of subjects
Change in waist circumference
cm
Change in systolic blood pressure
mmHg
Change in physical functioning score
Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health.
Change in physical function domain (5-items) score
The Impact of Weight on Quality of Life Lite for Clinical Trials Version (IWQoL-Lite for CT) questionnaire is a 20-item modified version of an instrument designed to assess weight-related quality of life.
Change in body weight
kg
Change in body mass index (BMI)
kg/m^2
Change in glycosylated haemoglobin (HbA1c)
Percent
Change in HbA1c
mmol /mol
Change in fasting plasma glucose (FPG)
mg/dL
Change in fasting serum insulin
mIU/L
Change in diastolic blood pressure
mmHg
Change in lipids: Total cholesterol
mg/dL
Change in lipids: High density lipoprotein (HDL) cholesterol
mg/dL
Change in lipids: Low density lipoprotein (LDL) cholesterol
mg/dL
Change in lipids: Very low density lipoprotein (VLDL) cholesterol
mg/dL
Change in lipids: Free fatty acids (FFA)
mg/dL
Change in lipids: Triglycerides
mg/dL
Change in SF-36: role-physical score
Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health.
Change in SF-36: bodily pain score
Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health.
Change in SF-36: general health score
Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health.
Change in SF-36: vitality score
Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health.
Change in SF-36: social functioning score
Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health.
Change in SF-36: role-emotional score
Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health.
Change in SF-36: mental health score
Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health.
Change in SF-36: physical component summary
Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health.
Change in SF-36: mental component summary
Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health.
Change in IWQoL-Lite for CT: pain/discomfort domain score
The Impact of Weight on Quality of Life Lite for Clinical Trials Version (IWQoL-Lite for CT) questionnaire is a 20-item modified version of an instrument designed to assess weight-related quality of life.
Change in IWQoL-Lite for CT: psychosocial domain score
The Impact of Weight on Quality of Life Lite for Clinical Trials Version (IWQoL-Lite for CT) questionnaire is a 20-item modified version of an instrument designed to assess weight-related quality of life.
Change in IWQoL-Lite for CT: total score
The Impact of Weight on Quality of Life Lite for Clinical Trials Version (IWQoL-Lite for CT) questionnaire is a 20-item modified version of an instrument designed to assess weight-related quality of life.
Subjects who achieve responder definition value for SF-36 physical functioning score (yes/no)
Number of subjects
Subjects who achieve responder definition value for IWQoL-Lite for CT physical function domain (5-items) score (yes/no)
Number of subjects
Change in glycaemic category
Normo-glycaemia, pre-diabetes or T2D
Change in antihypertensive medication
Decrease, no change, increase
Change in lipid-lowering medication
Decrease, no change, increase
Change in concomitant oral antidiabetic medication
Decrease, no change, increase (only applies to subjects with T2D at week 0)
Change in fatty liver index (FLI) score category
Below 30, equal to or above 30 and below 60, equal to or above 60
Subjects who have permanently discontinued randomised trial product (yes/no)
Number of subjects
Time to permanent discontinuation of randomised trial product
Weeks
Number of treatment emergent adverse events (TEAEs)
Count
Number of serious adverse events (SAEs)
Count
Number of treatment emergent severe or blood glucose (BG) confirmed symptomatic hypoglycaemia episodes (yes/no)
Count (only applies to subjects with T2D at week 0)
Change in pulse
Beats per minute (bpm)
Change in amylase
U/L
Change in lipase
U/L
Change in calcitonin
ng/L

Full Information

First Posted
January 30, 2020
Last Updated
June 26, 2023
Sponsor
Novo Nordisk A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT04251156
Brief Title
Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity
Acronym
STEP 7
Official Title
Effect and Safety of Semaglutide 2.4 mg Once-weekly on Weight Management in Subjects With Overweight or Obesity
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Completed
Study Start Date
December 8, 2020 (Actual)
Primary Completion Date
August 23, 2022 (Actual)
Study Completion Date
September 18, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will look at the change in body weight from the start to the end of the study. The purpose of the study is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the medicine participants will have talks with study staff about healthy food choices, how to be more physically active and what else they can do to lose weight. Participants will either get semaglutide or "dummy medicine" - which treatment is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skinfold in the stomach, thigh or upper arm.• The study will last for about 1 year. Participants will have 11 clinic visits and 8 phone calls with the study doctor. Participants will have 3 clinic visits where they cannot eat and drink (water is allowed) for up to 8 hours before the visit and 1 clinic visit where they cannot eat and drink for up to 2 hours before the visit. (4 visits and 1 visit, respectively, if they have type 2 diabetes (T2D)). Participants will have 4 clinic visits where they will have blood samples taken. (5 visits if they have T2D). For China: Participants will have 9 clinic visits where they will have blood samples taken. Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overweight, Obesity, Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Sponsor staff involved in the clinical trial is masked according to company standard procedures
Allocation
Randomized
Enrollment
375 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Semaglutide
Arm Type
Experimental
Arm Description
Once-weekly injections of gradually increased doses of semaglutide
Arm Title
Placebo (semaglutide)
Arm Type
Placebo Comparator
Arm Description
Once-weekly injections of gradually increased doses of semaglutide placebo
Intervention Type
Drug
Intervention Name(s)
Semaglutide
Intervention Description
Semaglutide administered subcutaneously (s.c., under the skin) as well as diet and physical activity counselling for 44 weeks. Doses gradually increased to 2.4 mg
Intervention Type
Drug
Intervention Name(s)
Placebo (semaglutide)
Intervention Description
Semaglutide placebo administered s.c. as an adjunct to a reduced-calorie diet and increased physical activity regimen for 44 weeks
Primary Outcome Measure Information:
Title
Change in body weight
Description
Percent
Time Frame
From baseline at week 0 to week 44
Title
Subjects who achieve body weight reduction equal to or above 5% (yes/no)
Description
Number of subjects
Time Frame
From baseline at week 0 to week 44
Secondary Outcome Measure Information:
Title
Subjects who achieve body weight reduction equal to or above 10% (yes/no)
Description
Number of subjects
Time Frame
From baseline at week 0 to week 44
Title
Subjects who achieve body weight reduction equal to or above 15% (yes/no)
Description
Number of subjects
Time Frame
From baseline at week 0 to week 44
Title
Change in waist circumference
Description
cm
Time Frame
From baseline at week 0 to week 44
Title
Change in systolic blood pressure
Description
mmHg
Time Frame
From baseline at week 0 to week 44
Title
Change in physical functioning score
Description
Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health.
Time Frame
From baseline at week 0 to week 44
Title
Change in physical function domain (5-items) score
Description
The Impact of Weight on Quality of Life Lite for Clinical Trials Version (IWQoL-Lite for CT) questionnaire is a 20-item modified version of an instrument designed to assess weight-related quality of life.
Time Frame
From baseline at week 0 to week 44
Title
Change in body weight
Description
kg
Time Frame
From baseline at week 0 to week 44
Title
Change in body mass index (BMI)
Description
kg/m^2
Time Frame
From baseline at week 0 to week 44
Title
Change in glycosylated haemoglobin (HbA1c)
Description
Percent
Time Frame
From baseline at week 0 to week 44
Title
Change in HbA1c
Description
mmol /mol
Time Frame
From baseline at week 0 to week 44
Title
Change in fasting plasma glucose (FPG)
Description
mg/dL
Time Frame
From baseline at week 0 to week 44
Title
Change in fasting serum insulin
Description
mIU/L
Time Frame
From baseline at week 0 to week 44
Title
Change in diastolic blood pressure
Description
mmHg
Time Frame
From baseline at week 0 to week 44
Title
Change in lipids: Total cholesterol
Description
mg/dL
Time Frame
From baseline at week 0 to week 44
Title
Change in lipids: High density lipoprotein (HDL) cholesterol
Description
mg/dL
Time Frame
From baseline at week 0 to week 44
Title
Change in lipids: Low density lipoprotein (LDL) cholesterol
Description
mg/dL
Time Frame
From baseline at week 0 to week 44
Title
Change in lipids: Very low density lipoprotein (VLDL) cholesterol
Description
mg/dL
Time Frame
From baseline at week 0 to week 44
Title
Change in lipids: Free fatty acids (FFA)
Description
mg/dL
Time Frame
From baseline at week 0 to week 44
Title
Change in lipids: Triglycerides
Description
mg/dL
Time Frame
From baseline at week 0 to week 44
Title
Change in SF-36: role-physical score
Description
Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health.
Time Frame
From baseline at week 0 to week 44
Title
Change in SF-36: bodily pain score
Description
Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health.
Time Frame
From baseline at week 0 to week 44
Title
Change in SF-36: general health score
Description
Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health.
Time Frame
From baseline at week 0 to week 44
Title
Change in SF-36: vitality score
Description
Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health.
Time Frame
From baseline at week 0 to week 44
Title
Change in SF-36: social functioning score
Description
Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health.
Time Frame
From baseline at week 0 to week 44
Title
Change in SF-36: role-emotional score
Description
Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health.
Time Frame
From baseline at week 0 to week 44
Title
Change in SF-36: mental health score
Description
Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health.
Time Frame
From baseline at week 0 to week 44
Title
Change in SF-36: physical component summary
Description
Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health.
Time Frame
From baseline at week 0 to week 44
Title
Change in SF-36: mental component summary
Description
Short Form 36 v2.0 acute (SF-36) is a 36-item, patient-reported survey of patient health. SF-36 measures the subject's overall Health Related Quality of Life on 8 domains: physical functioning, role functioning, bodily pain, general health, vitality, social functioning, role emotional and mental health.
Time Frame
From baseline at week 0 to week 44
Title
Change in IWQoL-Lite for CT: pain/discomfort domain score
Description
The Impact of Weight on Quality of Life Lite for Clinical Trials Version (IWQoL-Lite for CT) questionnaire is a 20-item modified version of an instrument designed to assess weight-related quality of life.
Time Frame
From baseline at week 0 to week 44
Title
Change in IWQoL-Lite for CT: psychosocial domain score
Description
The Impact of Weight on Quality of Life Lite for Clinical Trials Version (IWQoL-Lite for CT) questionnaire is a 20-item modified version of an instrument designed to assess weight-related quality of life.
Time Frame
From baseline at week 0 to week 44
Title
Change in IWQoL-Lite for CT: total score
Description
The Impact of Weight on Quality of Life Lite for Clinical Trials Version (IWQoL-Lite for CT) questionnaire is a 20-item modified version of an instrument designed to assess weight-related quality of life.
Time Frame
From baseline at week 0 to week 44
Title
Subjects who achieve responder definition value for SF-36 physical functioning score (yes/no)
Description
Number of subjects
Time Frame
Week 44
Title
Subjects who achieve responder definition value for IWQoL-Lite for CT physical function domain (5-items) score (yes/no)
Description
Number of subjects
Time Frame
Week 44
Title
Change in glycaemic category
Description
Normo-glycaemia, pre-diabetes or T2D
Time Frame
From baseline at week 0 to week 44
Title
Change in antihypertensive medication
Description
Decrease, no change, increase
Time Frame
From baseline at week 0 to week 44
Title
Change in lipid-lowering medication
Description
Decrease, no change, increase
Time Frame
From baseline at week 0 to week 44
Title
Change in concomitant oral antidiabetic medication
Description
Decrease, no change, increase (only applies to subjects with T2D at week 0)
Time Frame
From baseline at week 0 to week 44
Title
Change in fatty liver index (FLI) score category
Description
Below 30, equal to or above 30 and below 60, equal to or above 60
Time Frame
From baseline at week 0 to week 44
Title
Subjects who have permanently discontinued randomised trial product (yes/no)
Description
Number of subjects
Time Frame
From randomisation at week 0 to week 44
Title
Time to permanent discontinuation of randomised trial product
Description
Weeks
Time Frame
Week 0 - week 44
Title
Number of treatment emergent adverse events (TEAEs)
Description
Count
Time Frame
From week 0 to week 51
Title
Number of serious adverse events (SAEs)
Description
Count
Time Frame
From week 0 to week 51
Title
Number of treatment emergent severe or blood glucose (BG) confirmed symptomatic hypoglycaemia episodes (yes/no)
Description
Count (only applies to subjects with T2D at week 0)
Time Frame
From week 0 to week 51
Title
Change in pulse
Description
Beats per minute (bpm)
Time Frame
From baseline at week 0 to week 44
Title
Change in amylase
Description
U/L
Time Frame
From baseline at week 0 to week 44
Title
Change in lipase
Description
U/L
Time Frame
From baseline at week 0 to week 44
Title
Change in calcitonin
Description
ng/L
Time Frame
From baseline at week 0 to week 44

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female, age 18 years or older at the time of signing informed consent History of at least one self-reported unsuccessful dietary effort to lose body weight For subjects without T2D at screening: Body mass index (BMI) of : greater than or equal to 30 kg/m^2 greater than or equal to 27 kg/m^2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease For subjects with T2D at screening: Diagnosed with T2D above or equal to 180 days prior to the day of screening Treated with either: diet and exercise alone or stable treatment (same drug(s), dose and dosing frequency) for at least 60 days prior to the day of screening with up to 3 oral antidiabetic medications alone or in any combination (metformin, α-glucosidase inhibitor (AGI), SU, glinides, SGLT2i or glitazone) according to local label HbA1c 7.0-10.0% (53-86 mmol/mol) (both inclusive) BMI greater than or equal to 27 kg/m^2 Exclusion Criteria: A self-reported change in body weight above 5 kg (11 lbs) within 90 days before screening irrespective of medical records For subjects without T2D at screening: - HbA1c equal to or above 6.5% (48 mmol/mol) as measured by the central laboratory at screening For subjects with T2D at screening: Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of below 30 mL/min/1.73 m^2 (below 60 mL/min/1.73 m^2 in subjects treated with SGLT2i) according to CKDEPI creatinine equation as defined by KDIGO 2012 by the central laboratory at screening Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Reporting Anchor & Disclosure (1452)
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
Facility Name
Novo Nordisk Investigational Site
City
Aparecida de Goiania
State/Province
Goias
ZIP/Postal Code
74935-530
Country
Brazil
Facility Name
Novo Nordisk Investigational Site
City
São Paulo
State/Province
Sao Paulo
ZIP/Postal Code
01228-200
Country
Brazil
Facility Name
Novo Nordisk Investigational Site
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100853
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Beijing
State/Province
Beijing
ZIP/Postal Code
101200
Country
China
Facility Name
Novo Nordisk Investigational Site
City
ChongQing
State/Province
Chongqing
ZIP/Postal Code
404000
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Fuzhou
State/Province
Fujian
ZIP/Postal Code
350001
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Cangzhou
State/Province
Hebei
ZIP/Postal Code
061000
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Hengshui
State/Province
Hebei
ZIP/Postal Code
053000
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Shijiazhuang
State/Province
Hebei
ZIP/Postal Code
050000
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Huhehaote
State/Province
Inner Mongolia
ZIP/Postal Code
010020
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Huhhot
State/Province
Inner Mongolia
ZIP/Postal Code
010050
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Changzhou
State/Province
Jiangsu
ZIP/Postal Code
213003
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210011
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210029
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Suzhou
State/Province
Jiangsu
ZIP/Postal Code
215006
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Zhenjiang
State/Province
Jiangsu
ZIP/Postal Code
212001
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Changchun
State/Province
Jilin
ZIP/Postal Code
130021
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Jin'an
State/Province
Shandong
ZIP/Postal Code
250013
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200040
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200072
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200240
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200336
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
201200
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300052
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300211
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Kunming
State/Province
Yunnan
ZIP/Postal Code
650101
Country
China
Facility Name
Novo Nordisk Investigational Site
City
Shatin, New Territories
Country
Hong Kong
Facility Name
Novo Nordisk Investigational Site
City
Gyeonggi-do
ZIP/Postal Code
16499
Country
Korea, Republic of
Facility Name
Novo Nordisk Investigational Site
City
Seoul
ZIP/Postal Code
03080
Country
Korea, Republic of

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
IPD Sharing URL
http://novonordisk-trials.com

Learn more about this trial

Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity

We'll reach out to this number within 24 hrs